Epidemiology of acute myeloid leukemia in Virginia: Excellent survival outcomes for patients in rural Appalachia.
Academic Medical Centers
/ statistics & numerical data
Aged
Female
Hematopoietic Stem Cell Transplantation
/ statistics & numerical data
Humans
Induction Chemotherapy
/ statistics & numerical data
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute
/ epidemiology
Male
Middle Aged
Retrospective Studies
Rural Population
/ statistics & numerical data
Transplantation, Homologous
/ statistics & numerical data
Urban Population
/ statistics & numerical data
Virginia
/ epidemiology
AML
cytogenetics
geography
socioeconomic factors
telemedicine
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
20
01
2021
received:
19
09
2020
accepted:
04
02
2021
pubmed:
23
3
2021
medline:
5
2
2022
entrez:
22
3
2021
Statut:
ppublish
Résumé
Acute myeloid leukemia, the most common acute leukemia in adults, has a poor overall survival. Studies have suggested that certain socioeconomic factors such as living in a rural or farming area are associated with worse outcomes. Since 42% of acute myeloid leukemia patients seen in our academic center reside in a rural area, we have a unique opportunity to study outcomes of patients in rural versus urban settings. This analysis evaluates the effect of geography and socioeconomic factors on the biology, treatment, and overall survival of patients with acute myeloid leukemia, with the goal of understanding health care disparities. Patient characteristics, cytogenetic data, treatment history, and overall survival were collected and analyzed to identify differences between urban and rural residency. This cohort included 42% of patients who resided in a rural area at the time of acute myeloid leukemia diagnosis. There was no difference in overall survival between the cohorts. The 1 year overall survival for the entire cohort was 47.9%. There was no difference detected in rates of adverse cytogenetics between the rural and urban cohorts. Similar numbers of patients received induction chemotherapy or proceeded to allogeneic stem cell transplant between the cohorts. This study highlights that similar outcomes can be achieved in rural and urban patients, suggesting that intensive efforts at telehealth, education, and collaboration with local oncology practices may be beneficial.
Sections du résumé
BACKGROUND
Acute myeloid leukemia, the most common acute leukemia in adults, has a poor overall survival. Studies have suggested that certain socioeconomic factors such as living in a rural or farming area are associated with worse outcomes. Since 42% of acute myeloid leukemia patients seen in our academic center reside in a rural area, we have a unique opportunity to study outcomes of patients in rural versus urban settings.
AIM
This analysis evaluates the effect of geography and socioeconomic factors on the biology, treatment, and overall survival of patients with acute myeloid leukemia, with the goal of understanding health care disparities.
METHODS AND RESULTS
Patient characteristics, cytogenetic data, treatment history, and overall survival were collected and analyzed to identify differences between urban and rural residency. This cohort included 42% of patients who resided in a rural area at the time of acute myeloid leukemia diagnosis. There was no difference in overall survival between the cohorts. The 1 year overall survival for the entire cohort was 47.9%. There was no difference detected in rates of adverse cytogenetics between the rural and urban cohorts. Similar numbers of patients received induction chemotherapy or proceeded to allogeneic stem cell transplant between the cohorts.
CONCLUSIONS
This study highlights that similar outcomes can be achieved in rural and urban patients, suggesting that intensive efforts at telehealth, education, and collaboration with local oncology practices may be beneficial.
Identifiants
pubmed: 33751859
doi: 10.1002/cnr2.1354
pmc: PMC8388176
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1354Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Public Health Nurs. 2004 Mar-Apr;21(2):103-10
pubmed: 14987209
J Clin Epidemiol. 1994 Aug;47(8):903-9
pubmed: 7730894
Cancer Rep (Hoboken). 2021 Aug;4(4):e1354
pubmed: 33751859
N Engl J Med. 2019 Oct 31;381(18):1728-1740
pubmed: 31665578
Prev Chronic Dis. 2019 Jan 03;16:E01
pubmed: 30605423
Cancer. 2020 Dec 15;126(24):5319-5327
pubmed: 32910494
Blood. 2017 Aug 10;130(6):722-731
pubmed: 28588020
Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2446-8
pubmed: 16214930
JAMA. 2005 Dec 14;294(22):2879-88
pubmed: 16352796
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
J Community Health. 2012 Aug;37(4):804-13
pubmed: 22101638
Leukemia. 2019 Feb;33(2):379-389
pubmed: 30555165
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood Cancer J. 2018 Jan 10;8(1):4
pubmed: 29321554
Cancer Epidemiol. 2015 Dec;39(6):1084-92
pubmed: 26365691
Oncologist. 2011;16(8):1072-81
pubmed: 21873582
Health Serv Res. 2017 Aug;52(4):1473-1493
pubmed: 27500788
Cancer. 2008 Jan 1;112(1):181-92
pubmed: 18000806
Blood. 2004 Jun 1;103(11):4036-42
pubmed: 14976037
Environ Res. 2014 Aug;133:353-61
pubmed: 25038451
Cancer. 2015 Nov 1;121(21):3877-84
pubmed: 26367383
Adv Radiat Oncol. 2018 Aug 10;3(4):471-477
pubmed: 30370344
Int J Environ Res Public Health. 2019 Mar 26;16(6):
pubmed: 30917515
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):250-8
pubmed: 26819264
N Engl J Med. 2018 Jun 21;378(25):2386-2398
pubmed: 29860938
Biol Blood Marrow Transplant. 2019 Oct;25(10):2086-2090
pubmed: 31228584
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):992-997
pubmed: 28600296
J Rural Health. 2017 Sep;33(4):375-381
pubmed: 27602545
Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):82-89
pubmed: 29079128